Clinical Trial Update: Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating ruxolitinib in chronic myeloid leukemia patients with minimal residual disease on tyrosine kinase inhibitors was terminated. The update…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission | Phase 1 | Status: TERMINATED